BioDelivery Sciences International Competitors, Revenue, Alternatives and Pricing
Overview

State Ranking
Estimated Revenue & Financials
- BioDelivery Sciences International's estimated annual revenue is currently $5.6M per year.
- BioDelivery Sciences International received $50.0M in venture funding in May 2018.
- BioDelivery Sciences International's estimated revenue per employee is $30,054
- BioDelivery Sciences International's total funding is $105.5M.
Employee Data
- BioDelivery Sciences International has 185 Employees.
- BioDelivery Sciences International grew their employee count by 7% last year.
- BioDelivery Sciences International currently has 4 job openings.
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
Advertise Here | ||||||
$5.6M | 185 | 7% | N/A | - | N/A | |
$39.4M | 196 | 8% | N/A | - | N/A | |
$2147.5M | 24959 | N/A | N/A | - | N/A | |
$8.6M | 43 | 5% | N/A | - | N/A | |
$49.2M | 245 | -1% | N/A | - | N/A | |
$15.1M | 75 | 1% | N/A | - | N/A | |
$12.3M | 61 | 30% | N/A | - | N/A | |
$12.3M | 61 | 13% | N/A | - | N/A | |
$20.1M | 100 | 12% | N/A | - | N/A | |
$10.5M | 52 | -2% | N/A | - | N/A |
What Is BioDelivery Sciences International?
BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
keywords:Biotechnology,Healthcare,Pharmaceuticals185
Number of Employees
$5.6M
Revenue (est)
4
Current Jobs
7%
Employee Growth %
$105.5M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
BioDelivery Sciences International News
So we'll take a look at whether insiders have been buying or selling shares in BioDelivery Sciences International, Inc. (NASDAQ:BDSI).
08, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty ...
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET. Company ...
BioDelivery Sciences International Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2002-07-09 | $9.4M | Public Offering | Article | |
2005-07-19 | $7.0M | Undisclosed | Clinical Development Capital L | Article |
2005-08-05 | $7.0M | Undisclosed | Article | |
2006-02-17 | $7.0M | Undisclosed | CDC IV LLC | Article |
2012-11-29 | $40.0M | Undisclosed | William Blair & Company L L C | Article |
2014-02-11 | $60.0M | Undisclosed | Article | |
2015-06-02 | $20.7M | Undisclosed | MidCap Financial | Article |
2017-02-24 | $75.0M | Undisclosed | CRG LP, | Article |
2018-05-18 | $50.0M | Undisclosed | William Blair & Company, L.L.C. | Article |
BioDelivery Sciences International Executive Hires
Date | Name | Title | Reference |
---|---|---|---|
2005-08-24 | Mark A. Sirgo | Chief Executive Officer | Article |
2007-04-11 | Al Medwar | VP Marketing | Article |
2010-09-08 | Benny Ward | EVP Business/Strategic Development | Article |
2013-07-24 | Adrian Hepner | VP Clinical Research/Regulatory Affair | Article |
2013-10-22 | Ernest R. De Paolantonio | CFO/Corporate Secretary | Article |
2013-12-04 | David Acheson | VP Sales / Managed Markets | Article |
2014-10-13 | J. Chris Prue | EVP Regulatory Affairs /Quality Assurance | Article |
2015-04-29 | Sarah DeRossett | VP Clinical Research/Medical Affairs | Article |
2015-06-09 | Stephana E. Patton | VP/Geneal Counsel | Article |
2015-07-15 | Enoch Bortey | VP Clinical Biostatistics/Data Systems | Article |
2015-12-04 | Joseph M. Lockhart | VP Manufacturing and Supply Chain | Article |
2015-12-17 | Niraj Vasisht | SVP/CTO | Article |
2016-12-15 | Peter Ginsberg | Vice President of Business Development | Article |
2017-12-21 | Scott Plesha | President/Sales & Marketing functions | Article |
2018-05-08 | Herm Cukier | CEO | Article |
2018-07-31 | Thomas Smith | Chief Medical Officer | Article |
2019-01-16 | Terry Coelho | Chief Financial Officer | Article |